TLR7 and melanoma: To explore the local and distant antitumor potential of the TLR7/8 agonist IMQ, we employed orthotopic and syngeneic melanoma and breast cancer models (Extended Data Fig. 1a,b), as such tumors are easily accessible in patients for topical treatment and often form distant metastases15.